Compare IPCA Labs with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs J.B.CHEMICALS - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS J.B.CHEMICALS IPCA LABS/
J.B.CHEMICALS
 
P/E (TTM) x 23.1 16.8 137.2% View Chart
P/BV x 4.5 2.3 192.7% View Chart
Dividend Yield % 0.1 0.5 20.7%  

Financials

 IPCA LABS   J.B.CHEMICALS
EQUITY SHARE DATA
    IPCA LABS
Mar-18
J.B.CHEMICALS
Mar-18
IPCA LABS/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs695363 191.5%   
Low Rs400255 156.9%   
Sales per share (Unadj.) Rs260.2169.1 153.8%  
Earnings per share (Unadj.) Rs19.016.6 114.3%  
Cash flow per share (Unadj.) Rs33.123.4 141.2%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.6 28.2%  
Book value per share (Unadj.) Rs213.0172.5 123.5%  
Shares outstanding (eoy) m126.2083.57 151.0%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.11.8 115.2%   
Avg P/E ratio x28.918.6 155.1%  
P/CF ratio (eoy) x16.613.2 125.5%  
Price / Book Value ratio x2.61.8 143.5%  
Dividend payout %5.312.0 43.7%   
Avg Mkt Cap Rs m69,12025,827 267.6%   
No. of employees `00013.33.8 351.4%   
Total wages/salary Rs m7,3592,511 293.1%   
Avg. sales/employee Rs Th2,477.43,747.4 66.1%   
Avg. wages/employee Rs Th555.2665.7 83.4%   
Avg. net profit/employee Rs Th180.6367.8 49.1%   
INCOME DATA
Net Sales Rs m32,83614,135 232.3%  
Other income Rs m418366 114.3%   
Total revenues Rs m33,25414,501 229.3%   
Gross profit Rs m4,5052,178 206.8%  
Depreciation Rs m1,777570 312.0%   
Interest Rs m24035 688.3%   
Profit before tax Rs m2,9051,940 149.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m511552 92.5%   
Profit after tax Rs m2,3941,387 172.6%  
Gross profit margin %13.715.4 89.0%  
Effective tax rate %17.628.5 61.8%   
Net profit margin %7.39.8 74.3%  
BALANCE SHEET DATA
Current assets Rs m19,45510,470 185.8%   
Current liabilities Rs m10,0762,749 366.5%   
Net working cap to sales %28.654.6 52.3%  
Current ratio x1.93.8 50.7%  
Inventory Days Days9855 177.4%  
Debtors Days Days6778 86.2%  
Net fixed assets Rs m20,2605,811 348.6%   
Share capital Rs m252167 151.0%   
"Free" reserves Rs m26,63314,248 186.9%   
Net worth Rs m26,88614,416 186.5%   
Long term debt Rs m2,3400-   
Total assets Rs m41,17317,649 233.3%  
Interest coverage x13.156.6 23.1%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.80.8 99.6%   
Return on assets %6.48.1 79.4%  
Return on equity %8.99.6 92.5%  
Return on capital %10.813.7 78.6%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,6426,164 253.8%   
Fx outflow Rs m4,8841,334 366.0%   
Net fx Rs m10,7594,829 222.8%   
CASH FLOW
From Operations Rs m3,4111,231 277.2%  
From Investments Rs m-1,354-208 650.6%  
From Financial Activity Rs m-1,304-595 219.1%  
Net Cashflow Rs m753427 176.4%  

Share Holding

Indian Promoters % 45.9 55.4 82.9%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 11.4 3.4 336.3%  
FIIs % 25.3 3.9 648.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 37.0 47.0%  
Shareholders   36,892 30,437 121.2%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

J.B.CHEMICALS Announces Quarterly Results (4QFY19); Net Profit Up 91.2% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, J.B.CHEMICALS has posted a net profit of Rs 422 m (up 91.2% YoY). Sales on the other hand came in at Rs 4 bn (up 18.9% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.

J.B.CHEMICALS 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of J.B.CHEMICALS for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of J.B.CHEMICALS. Also includes updates on the valuation of J.B.CHEMICALS.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 20, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - CADILA HEALTHCARE COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS